CSIMarket
 
Tango Therapeutics Inc   (TNGX)
Other Ticker:  
 
 
Price: $9.0300 $-0.06 -0.660%
Day's High: $9.295 Week Perf: -15.92 %
Day's Low: $ 8.93 30 Day Perf: -24.44 %
Volume (M): 3,317 52 Wk High: $ 13.03
Volume (M$): $ 29,951 52 Wk Avg: $7.11
Open: $9.06 52 Wk Low: $2.47



 Market Capitalization (Millions $) 876
 Shares Outstanding (Millions) 97
 Employees -
 Revenues (TTM) (Millions $) 38
 Net Income (TTM) (Millions $) -100
 Cash Flow (TTM) (Millions $) -42
 Capital Exp. (TTM) (Millions $) 2

Tango Therapeutics Inc
Tango Therapeutics Inc is a biotechnology company that is focused on developing precise cancer therapies utilizing a next-generation approach. The company leverages the latest advancements in genomics and CRISPR screening technology to identify and target cancer vulnerabilities. Their platform aims to deliver personalized and precise treatments that can overcome drug resistance and improve patient outcomes. Tango Therapeutics Inc is dedicated to transforming the way cancer is treated by developing novel therapeutics that address the underlying genetic causes of the disease.


   Company Address: 201 Brookline Ave. Boston 2215 MA
   Company Phone Number: 320-4900   Stock Exchange / Ticker: NASDAQ TNGX
   TNGX is expected to report next financial results on March 26, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Tango Therapeutics Set to Present at Renowned Investor Conferences, Highlighting Cutting-Edge Research in Precision Cancer Medicines.

Published Wed, Mar 6 2024 12:00 PM UTC

Tango Therapeutics, a prominent clinical-stage biotechnology company, recently made an exciting announcement regarding its upcoming participation in several investor conferences. The company prides itself on its dedication to discovering and delivering precision cancer medicines, and this involvement in industry events demonstrates its commitment to advancing cancer research...

Shares

Tango Therapeutics' Bold Move: Stock Options Unleashed to Fuel Cancer Precision Revolution

Published Fri, Jan 5 2024 9:05 PM UTC



In a bid to revolutionize the field of precision cancer medicines, Tango Therapeutics, a clinical-stage biotechnology company, recently announced the granting of non-qualified stock options and restricted stock units (RSUs) to a new employee under their 2023 Inducement Plan. This move demonstrates Tango Therapeutics' commitment to attracting top talent and driving ...

Clinical Study

Unleashing Precision Medicine: Tango Therapeutics Steps into Uncharted Territory with TNG348 in BRCA1/2-Mutant and HRD+ Cancers

Published Wed, Jan 3 2024 12:01 PM UTC

Tango Therapeutics Initiates Phase 1/2 Trial of TNG348 in BRCA1/2-Mutant and HRD+ CancersTango Therapeutics, a renowned clinical-stage biotechnology company specializing in precision cancer medicines, recently announced a major milestone in their research. The company revealed that the first patient has been dosed in the phase 1/2 trial evaluating TNG348 as a monotherapy an...

Tango Therapeutics Inc

Tango Therapeutics Inc. Reports Stunning Loss of $-0.23 per Share, Shakes Market Confidence

Tango Therapeutics Inc, a leading company in the Major Pharmaceutical Preparations sector, recently released its fiscal period results for the period ending September 30, 2023. Despite a net loss of $-0.23 per share, the company showed improvement compared to the previous year's loss of $-0.33 per share. Furthermore, the company's revenue increased by an impressive 55.087% to $10.73 million, compared to $6.92 million in the corresponding period a year before.
Although sequentially, the revenue fell by -26.483% from $14.60 million, Tango Therapeutics' growth in the third quarter of 2023 correlates favorably to its peers in the Major Pharmaceutical Preparations sector, who reported an overall 2.06% increase in revenue during the same period.






 

Tango Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com